BioAge Labs, Inc. (BIOA)
5.075
-0.28
(-5.14%)
USD |
NASDAQ |
Oct 16, 12:11
BioAge Labs SG&A Expense (TTM) : 28.84M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 28.84M |
| March 31, 2026 | 28.76M |
| December 31, 2025 | 27.81M |
| September 30, 2025 | 26.94M |
| June 30, 2025 | 25.00M |
| March 31, 2025 | 22.45M |
| December 31, 2024 | 19.16M |
| Date | Value |
|---|---|
| September 30, 2024 | 13.02M |
| June 30, 2024 | 11.64M |
| March 31, 2024 | 11.02M |
| December 31, 2023 | 11.00M |
| September 30, 2023 | 11.00M |
| June 30, 2023 | 7.645M |
| March 31, 2023 | 3.467M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Neumora Therapeutics, Inc. | 53.16M |
| Alumis, Inc. | 77.08M |
| ANI Pharmaceuticals, Inc. | 324.76M |
| Corcept Therapeutics, Inc. | 556.47M |
| Veru, Inc. | 16.05M |